Income before deduction of interest, taxes and amortization: Intra-Cellular Therapies (ITCI)
The growth of Intra-Cellular Therapies (ITCI) relies on the demand for Caplyta and the expansion of insurance coverage limits. Experienced management is effectively scaling sales by leveraging market confidence. This chart of cash operating profit before deductions demonstrates liquidity dynamics, where the mark indicates the efficiency level. Revenues are generated through the treatment of patients with schizophrenia and bipolar disorder in specialized clinics.
Intra-Cellular Therapies, Inc. (ITCI) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Intra-Cellular Therapies|ITCI - Long-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies Inc.|ITCI - Company Debts|Debt to Book Capitalization Ratio Intra-Cellular Therapies|ITCI - Company Long-Term Debt|Company Short-Term Debt Intra-Cellular Therapies|Quick Ratio intracellulartherapies.com
- business earnings and investment ratios data:
ITCI - Company Net Income|Expected Profit Intra-Cellular Therapies|ITCI - P/E Multiple|Forward P/E Multiple Intra-Cellular Therapies Inc.|ITCI - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Intra-Cellular Therapies|ITCI - Operating profit before deduction of amortization|Earnings per share for the trailing year Intra-Cellular Therapies|ITCI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months intracellulartherapies.com|ITCI - Earnings growth in current year|Expected earnings per share trend next year Intra-Cellular Therapies
Analysis of all company metrics:Intra-Cellular Therapies (ITCI)
This indicator measures the business's ability to generate cash flow from core operations before deducting depreciation and interest, reflecting the actual efficiency of the operating cycle. By analyzing the monthly EBITDA trend, an investor can assess the dependence of Intra-Cellular Therapies (ITCI) on Caplyta sales, where any decline in profit signals regulatory pressure or patent risks, warning against the purchase of an overvalued asset.
Competitors of Intra-Cellular Therapies (ITCI)
Company profit before taxes, interest and amortization BIIB (Biogen Idec)|NBIX - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGC (regencellbioscience.com)|AXSM: Operating profit EBITDA|ACADIA Pharma (ACAD) - Operating profit EBITDA|Operating profit before deduction of amortization XENE|VKTX - Operating profit before depreciation charges|Operating profit EBITDA SUPN|Operating profit before deduction of amortization catalystpharma.com CPRX|Operating profit EBITDA DNLI (Denali Therapeutics Inc.)|Harmony Biosciences Inc (HRMY) - Profit before interest, taxes and amortization|BHVN - Profit before payment of interest, taxes and amortization|AMLX: Profit before payment of interest, taxes and amortization|Trevi Therapeutics (TRVI) - Profit before payment of interest, taxes and amortization|PRAX (praxismedicines.com) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization AVXL|Operating profit EBITDA CeriBell Inc|Profit before payment of interest, taxes and amortization Prothena Corp (PRTA)|Profit before payment of interest, taxes and amortization ALEC (alector.com)|Operating profit EBITDA ANNX (Annexon, Inc.)|Operating profit EBITDA Omeros Corp OMER|NGNE - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization ACIU (AC Immune S.A.)|VYGR (Voyager Pharma) - Operating profit before deduction of amortization|Neumora Corp - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization SCLX|TVGN (tevogen.com) - Company profit before taxes, interest and amortization|Operating profit EBITDA ACOG|CGTX (Cognition Therapeutics Inc.) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA IKT (Inhibikase)|Cassava Pharma (SAVA) - Profit before interest, taxes and amortization|ASRT - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization COYA (Coya Therapeutics, Inc.)|VTGN: Operating profit EBITDA|Ovid Therapeutics (OVID) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Acumen Pharma|CervoMed Corporation - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA ATHE|Operating income before deduction of amortization clene.com|Operating profit EBITDA PEPG (PepGen)|Jupiter Neurosciences, Inc. (JUNS) - Profit before interest, taxes and amortization|RLMD - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Annovis Bio Corporation ANVS|GRCE: Operating profit EBITDA|AIFF - Operating income before deduction of amortization|Operating profit before deduction of amortization KLTO|NRSN (NeuroSense Therapeutics, Ltd.) - Company profit before taxes, interest and amortization|Operating profit EBITDA RVPH|Operating profit before deduction of amortization metaviatx.com MTVA|Operating profit EBITDA NRXS (NeurAxis, Inc.)|Operating income before deduction of amortization Helius Medical Technologies, Inc. (HSDT)|PASG - Profit before payment of interest, taxes and amortization|NEUP (Neuphoria Therapeutics Inc.) - Operating profit before amortization|NERV: Operating profit EBITDA|Profit before interest, taxes and amortization Athira Pharma Corp (ATHA)|Operating profit before deduction of amortization ADXN|Operating profit EBITDA Alzamend|Profit before payment of interest, taxes and amortization Cyclerion Therapeutics (CYCN)|PTIX (protagenic.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pasithea Therapeutics Corp. KTTA|Cortigent Inc (CRGT) - Profit before interest, taxes and amortization|Avenue Therapeutics - Operating profit EBITDA|Operating income before deduction of amortization brainstorm-cell.com BCLI|Cara Therapeutics (CARA) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CHRO|Operating profit before deduction of amortization ELYM|LBPH (Longboard) - Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization Marinus Pharmaceuticals (MRNS)|NKGN (nkgenbiotech.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA NRBO (NeuroBo Pharmaceuticals, Inc.)|Operating profit EBITDA Sage Therapeutics Inc. SAGE|SNPX: Operating profit before deduction of amortization|Operating profit before depreciation charges Trevena Inc (TRVN)|VIGL: Operating profit EBITDA|Operating profit before deduction of amortization anewmeds.com|CERE (Cerevel Therapeutics, Inc.) - Operating profit EBITDA
